A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy

Mark Haas1, Jacobien C Verhave2, Zhi-Hong Liu3

  • 1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California; mark.haas@cshs.org.

Insights

Glomerular crescents in IgA nephropathy predict worse kidney outcomes, especially in patients not on immunosuppression. The study proposes new crescent scores (C1, C2) to enhance the Oxford Classification for better risk stratification.

Area of Science:

  • Nephrology
  • Pathology
  • Renal Medicine

Background:

  • The Oxford Classification for IgA nephropathy (IgAN) is crucial for prognostication but omits glomerular crescents.
  • Previous studies on crescents' predictive value were limited by excluding patients with severe renal insufficiency.

Purpose of the Study:

  • To evaluate crescents as a predictor of renal outcomes in a large IgAN cohort.
  • To determine if the proportion of crescent-containing glomeruli impacts survival from a composite endpoint of ≥50% eGFR decline or End-Stage Renal Disease (ESRD).

Main Methods:

  • A pooled analysis of 3096 patients from four retrospective IgAN studies.
  • Statistical analysis adjusted for covariates from the original Oxford classification.
  • Assessment of crescents' association with a combined renal event (≥50% eGFR decline or ESRD).

Main Results:

  • Overall, crescents predicted a higher risk of the combined renal event, particularly in patients not receiving immunosuppression.
  • Having crescents in ≥1/4 of glomeruli was associated with a significantly increased hazard ratio for the combined event (HR 2.29; 95% CI 1.35-3.91).
  • This association remained significant independently in both immunosuppression and non-immunosuppression groups.

Conclusions:

  • Glomerular crescents are significant independent predictors of poor renal outcomes in IgAN.
  • Proposed crescent scores (C0, C1, C2) can refine the Oxford Classification for improved risk stratification.
  • These scores can identify patients at high risk, guiding treatment decisions, even with immunosuppression.